← GLP-1 receptor agonists × body weight & composition

TrialLancet (London, England)2017

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.

Carel W le Roux et al.PubMed ↗Publisher ↗

A later paper about NCT01272219. The trial’s primary report, PMID 26132939, speaks for it on the map; the numbers here are shown and do not vote.

  • Liraglutidelooks good hereLower weight loss.Randomised, large.

What the trial testedrandomised · 2,254 people · 2017

Randomised vs placebo

Lowered weight loss

Doesn’t vote: a later paper about the trial

−4.30percentage points−4.90 to −3.70

liraglutide vs placebo

As reported

difference −4.3 %, 95% CI −4.90 to −3.70

Who was studied, and how

3,731people in the Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities trial, from 2011
2,254of them with obesity, in this paper

The trial randomly assignedassigned by chance

liraglutide
placebo

Lowered weight loss−4.30

randomised

the abstract, start to end

… [6.3]; estimated treatment difference -4.3%, 95% CI -4.9 to -3.7, …

← favours treatmentfavours comparator →
could be chance
Weight lossliraglutide vs placebo
−4.3−4.90 to −3.70
GLP-1 receptor agonistsBody weight & composition
1 / 4

369 papers cite itlatest 60 shown

2017
…
2023
2024
2025
2026
this paperpooled ittrialcites it

2 trials

Full record →Abstract, authors, funding and every citing paper · PMID 28237263